Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 32Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 16Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Colorectal Neoplasms 11Sarcoma 9Lung Neoplasms 9Nasopharyngeal Carcinoma 7Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Head and Neck Neoplasms 5Glioma 5Esophageal Neoplasms 5Cholangiocarcinoma 5Recurrence 4Pancreatic Neoplasms 4Osteosarcoma 4Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Advanced Gastric Cancer 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Neoplasm Metastasis 3NSCLC 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

margetuximab 1apatinib 1Vinorelbine 1Trastuzumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Cancer Metastatic × apatinib × Clear all
NCT03086785 2018-01-17

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡